2. >>R&D
  3. >>Clinical Trials

Vertex’s Suzetrigine Disappoints In Phase II Pain Study, But Phase III Planning Under Way

Acute Pain Approval Decision Due 30 January

 
• By Mandy Jackson

The NaV1.8 inhibitor showed a statistically significant change from baseline in lumbosacral radiculopathy pain, but it was the same as the reduction in the study’s placebo arm.

Lumbosacral radiculopathy is key to a larger peripheral neuropathic pain indication (Shutterstock)

Vertex Pharmaceuticals is awaiting a US Food and Drug Administration approval decision by 30 January for suzetrigine (VX-548) in the treatment of acute pain, but the blockbuster potential of the closely watched NaV1.8 inhibitor may rest largely on its ability to treat chronic pain. However, suzetrigine delivered disappointing Phase II results on 19 December in chronic treatment of lumbosacral radiculopathy (LSR) pain, although planning still is under way for a Phase III LSR program.

Vertex Stands Ready To Launch First Drug In Its Pain Franchise

NaV Channel Research Has Been A Long Journey: Vertex may win US FDA approval in January for the first novel pain drug in decades, after investing a lot of time and inventing new technology to unravel the science behind suzetrigine.

More from Clinical Trials

More from Scrip

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.